natgillin/translations-raw huggingface dataset:
(Se venligst markedsførers information om risiko ved lidokainhydroklorid i de relevante informations dokumenter for de respektive anvendte lidokain opløsninger).
(Please note the manufacturer's information on the risks of lidocaine hydrochloride in the relevant information documents on the respective lidocaine preparations used).
Se også pkt.
Treatment with injection into a muscle is only justified in exceptional cases and after a careful risk/ benefit evaluation.
2. ” Vær særlig forsigtig med at anvende Ceftriaxon Tyrol Pharma ” 1g.
See also section 2 “ Take special care with Ceftriaxone Tyrol Pharma 1g”.
For andre administrationsveje er andre styrker af Ceftriaxon Tyrol Pharma tilgængelige.
53 For other routes of administration other strengths of Ceftriaxone Tyrol Pharma are available.
Blandbarhed Rent principielt, bør ceftriaxon opløsninger altid administreres separat fra andre infusionsopløsninger.
Miscibility As a matter of principle, ceftriaxone solutions must always be administered separately from other solutions for infusion.
Ceftriaxon må under ingen omstændigheder blandes med opløsninger der indeholder calcium.
Under no circumstances must ceftriaxone solutions be mixed with solutions containing calcium.
Ceftriaxon Tyrol Pharma 1 g bør aldrig blandes med nogen af de følgende opløsninger:
Ceftriaxone Tyrol Pharma 1g must never be mixed with any of the following solutions:
- opløsninger der indeholder calcium så som Hartmann’ s og Ringer’ s opløsninger.
- solutions containing calcium such as Hartmann's and Ringer's solutions.
- aminoglykosider (ved parallel administration skal disse opløsninger administreres separat).
- aminoglycosides (when given concurrently, these preparations must be administered separately)
- Ceftriaxon Tyrol Pharma 1 g må ikke administreres i de samme sprøjter som andre
- Ceftriaxone Tyrol Pharma 1g must not be administered in the same syringe as other antibiotics
antibiotika eller andre bactericide præparater.
or other bactericidal agents.
INDLÆGSSEDDEL
54 PACKAGE LEAFLET:
52 Ceftriaxon Tyrol Pharma Ceftriaxon 2 g, pulver til infusionsvæske, opløsning (ceftriaxondinatrium)
Ceftriaxone Tyrol Pharma 2g, powder for solution for infusion (ceftriaxone sodium)
Hvad Ceftriaxon Tyrol Pharma er, og hvad det anvendes til 2.
What Ceftriaxone Tyrol Pharma 2g is and what it is used for 2.
Hvad du skal gøre, før du begynder at anvende Ceftriaxon Tyrol Pharma 3.
Before you use Ceftriaxone Tyrol Pharma 2g 3.
Hvordan du anvender Ceftriaxon Tyrol Pharma 4.
How to use Ceftriaxone Tyrol Pharma 2g 4.
Hvordan du opbevarer Ceftriaxon Tyrol Pharma 6.
How to store Ceftriaxone Tyrol Pharma 2g 6.
Hvad ceftriaxon Tyrol Pharma er og hvad det anvendes til
What Ceftriaxone Tyrol Pharma 2g is and what it is used for
Ceftriaxon kan anvendes til behandling af: blodforgiftning infektioner i hjernehinden (meningitis) infektioner i led og knogler infektioner i luftvejene (respiratoriske) infektioner i hud og bløddele (f. eks. væv)
Ceftriaxone can be used to treat: blood poisoning (sepsis) infection of the meninges (meningitis) bone or joint infections infections of the respiratory tract infections in the skin soft tissues
Hvad su skal gøre, før du begynder at anvende Ceftriaxon Tyrol Pharma
Before you use Ceftriaxone Tyrol Pharma 2g
Du bør ikke anvende Ceftriaxon Tyrol Pharma: hvis du er overfølsom (allergisk) over for ceftriaxon eller andre af indholdsstofferne i lægemidlet. hvis du er overfølsom (allergisk) over for andre typer af cefalosporin antibiotika.
You are allergic (hypersensitive) to ceftriaxone or to any of the other ingredients of this medicine You are allergic (hypersensitive) to any other cephalosporin type of antibiotic.
53 hvis du tidligere har haft alvorlige allergiske reaktioner over andre typer af penicillin – eller andre typer af beta- laktamer (antibiotika), da du så også vil være allergisk overfor denne medicin.
You have ever had a severe allergic reaction to any sort of penicillin - or to an other beta-laktam- antibiotic because you might also be allergic to this medicine.
Ceftriaxon Tyrol Pharma 2 g, må ikke gives til nyfødte med gulsot (hyperbilirubinæmi) eller for tidligt nyfødte, da anvendelse af ceftriaxon kan forårsage komplikationer med mulige hjerneskader hos disse patienter.
55 Ceftriaxone Tyrol Pharma 2g should not be used in newborn with jaundice (hyperbilirubinaemia) or preterm newborn because the use of ceftriaxone, the active substance of Ceftriaxone Tyrol Pharma 2g can leed to complications with possible brain damage in these patients.
Ceftriaxon Tyrol Pharma 2 g må ikke anvendes sammen med calciumbehandling, på grund af risikoen for udfældning af ceftriaxon- calcium hos for tidligt nyfødte.
Ceftriaxone Tyrol Pharma 2g should not be used together with calcium treatment, because of the risk of precipitation of ceftriaxone-calcium salt in term newborn.
Vær særlig forsigtig med at anvende Ceftriaxon Tyrol Pharma 2g: hvis du har eller har haft allergiske reaktioner overfor antibiotika, kontakt da din læge eller apoteket før du tager denne medicin hvis du nogensinde har haft andre typer af allergiske rektioner eller astma.
You have ever had an allergic reaction to any antibiotic, tell your doctor or pharmacist before you take this medicine You have ever had other type of allergic reaction or asthma.
Graviditet og amning Er du gravid eller påtænker du at blive gravid?
Pregnancy and breast feeding Are you pregnant, or do you think you might be pregnant?
Spørg din læge eller apoteket til råds, inden du tager nogen form for medicin.
Ask your doctor or pharmacist for advice before you use Ceftriaxone Tyrol Pharma 2g.
54 Bilkørsel og betjening af maskiner Du kan blive svimmel, når du tager denne medicin, hvilket kan påvirke din evne til at køre eller betjene maskiner.
This may affect your ability to drive or operate machinery.
Vigtige oplysninger om visse af indholdsstofferne i Ceftriaxon Tyrol Pharma Ceftriaxon indeholder 7. 2 mmol (166 mg) natrium pr dosis.
7.2mmol) sodium per dose.
Ceftriaxon Tyrol Pharma administreres normalt af en læge eller sygeplejerske. som en infusion. infusionen kan gives som en langsom infusion i en vene.
The infusion is given as a slow infusion into a vein.
1- 2 g én gang daglig Ved alvorlige infektioner, kan den daglige dosis øges til 4 g én gang daglig i en vene.
Adults, older people and children 12 years and over who weigh more than 50Kg 1 to 2g once a day In serious infections, this can be increased to 4g a day, injected into a vein.
Selv ikke ved alvorlige infektioner, må der ikke gives mere end 50 mg per kg.
Children between 15 days and 12 years old 20-80mg for each kg of body weight once a day, injected into a vein More than 80mg per kg must not be given, even in severe infections-except in meningitis.
Sædvanligvis gives kun en dosis.
Usually only one dose is given For people with kidney problems, the dose does not need to be reduced, if hepatic function is normal.
For patienter med nyreproblemer, behøver dosis ikke at justeres medmindre nyrefuntionen er stærkt nedsat.
If the condition of the kidney is very poor (creatinine clearance of < 10 ml/ min), the daily dose of ceftriaxone should not exceed 2 g in adult patients.
Hvis både nyre og leverfunktion er stærkt nedsat bør koncentrationer af ceftriaxon i blodet overvåges regelmæssigt og dosis justeres hensigtsmæssigt for børn og voksne Hvis du er i dialysebehandling, vil din læge foretage prøver for at sikre at du får den rette dosis.
If you are on dialysis, the doctor will do tests to make sure you are on the right dose.
Behandlingsvarigheden er sædvanligvis mindst 2 dage Den kan forsætte i op til 7 - 14 dage
The length of treatment is usually at least 2 days beyond the normalisation of body temperature.
55 Hvis du anvender mere Ceftriaxon Tyrol Pharma, end du bør Kontakt straks lægen, skadestuen, eller apoteket, hvis du har taget mere af ceftriaxon, end der står i denne information, eller mere end lægen har foreskrevet.
If you use more Ceftriaxone than you should If too much Ceftriaxone was used than it should be, talk to your doctor straight away or go to the nearest hospital accident and emergency department.
Hvis det er muligt, så tag æsken med, så du kan vise lægen hvilke tabletter du har taget.
Take the medicine with you in the carton, so that the staff will know exactly what has been used.
Du må ikke stoppe med at tage medicinen, selvom du føler dig bedre.
57 It is important that this medicine is used in the prescribed course which should not be interrupted only because you feel well again.
Hævelse af øjenlåg, ansigt
- Allergic reactions such as sudden wheeziness and tightness of the chest, swelling of the eyelids,
eller læber, alvorlige hududslæt med blæredannelse f. eks. i øjne, mund, hals og kønsorganer, bevidsthedstab (besvimelse).
face or lips, severe skin rashes that can blister and may involve the eyes, mouth and throat and genitals, loss of consciousness (fainting).
Smerter og hårhed, når injektionen gives i en venel Smerter og rødme, ved injektion i en vene.
Common side effects (affects less than 1 out of 10 people): allergic reactions (skin rash, itching, nettle rash, swellings of the skin and joints) changes in blood tests that check how your liver is working pain and hardness when injected into a muscle pain and redness when injected into a vein
Ikke almindelige bivirkninger (forekommer hos færre end 1 ud af 100 behandlede):
Uncommon side effects (affects less than 1 out of 100 people) nausea, vomiting, abdominal pain, loose stool or diarrhoea sores, inflammation of the tongue, loss of appetite headache, dizziness Infections:
Spiseforstyrrelser, appetiitløshed Hovedpine, svimmelhed Infektioner:
Having a course of ceftriaxone can temporarily increase the chance that you can get infections caused by other pathogens.
En ceftriaxon behandling, kan midlertidigt øge risikoen for en infektion, som er forårsaget af andre sygdoms fremkaldene bakterier, som f. eks. svamp.
For example, thrush may occur Kidney problems: changed in kidney function and reduced urine production
Leverforstyrrelser: ændringer i nyrefunktionen og nedsat urinproduktion.
Rare side effects (affects less than 1 out of 1,000 people) severe cramps in the belly (caused by inflammation of the pancreas) Gall stones in adults drops in the numbers of white blood cells (sometimes severe with increased risk of severe infection) Kidney stones in children
netsted:
Very rare side effects (affects less than 1 out of 10,000 people) reduced or damaged blood cells (increased chance of bleeding, bruising or infection) a type of anaemia that can be severe and is caused by red blood cells breaking up.
http: // www. laegemiddelstyrelsen. dk /.
58 If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist.
Hvordan du opbevarer Ceftriazon Tyrol Pharma
How to store Ceftriaxone Tyrol Pharma 2g
Enhver tilberedt ubrugt injektion eller infusion skal destrueres.
Any unused infusion solution should be disposed of.
Hvad Ceftriaxon Tyrol pharma 2 g, pulver til infusionsvæske, opløsning indeholder:
What Ceftriaxone Tyrol Pharma 2g contains:
Ceftriaxon Tyrol Pharma 2g Det aktive stof er ceftriaxondinatrium 3. 5 H2 O.
Ceftriaxone Tyrol Pharma 2g The active substance is ceftriaxone disodium 3.5 H2O.
Produktets udseende og pakningstørrelse Ceftriaxon Tyrol pharma 2 g:
What Ceftriaxone Tyrol Pharma 2g looks like and contents of the pack
Pulver til infusionsvæske, opløsning:
Ceftriaxone Tyrol Pharma 2g: powder for solution for infusion
Den tilberedte opløsning (klar til brug) er lysegul eller ravgul.
The ready-to-use solutions are pale yellow to amber.
57 Anvend ikke Ceftriaxon Tyrol pharma 2g hvis du bemærker følgende:
Do not use Ceftriaxone Tyrol Pharma 2 g if you notice the following:
Opløsningen er ikke klar.
The solution is not clear.
Ceftriaxon Tyrol pharma2 g, pulver ti infusionsvæske, opløsning leveres
Ceftriaxone Tyrol Pharma 2g, powder for solution for infusion, is supplied in packs of 1, 5 and 10 infusion bottles as well as in hospital packs.
Indehaver af markedsføringstilladelse Sandoz GmbH Biochemiestrasse 10 A- 6250 Kundl Østrig
Marketing Authorisation holder and manufacturer Sandoz GmbH Biochemiestraße 10 A-6250 Kundl Austria
--------------------------------------------------------------------------------------------------------------------------- Følgende oplysninger er kun tiltænkt læger og sundhedspersonale:
59 ------------------------------------------------------------------------------------------------------
Metode og administrationsvej for Ceftriaxon Tyrol Pharma 2 g, pulver til infusionsvæske, opløsning
The following information is intended for medical or healthcare professionals only:
Ceftriaxon Tyrol Pharma, 2 g injiceres i en vene (intravenøs administration).
Method and route of administration of Ceftriaxone Tyrol Pharma 2 g powder for solution for infusion
Intravenøs infussion (infusion i venen).
Ceftriaxone Tyrol Pharma 2g is injected into a vein (intravenous administration).
Indholdet i hætteglasset opløses ved omrystning i 40 ml af en af følgende calciumfrie infusionsvæsker: natriumklorid 0, 9%, natriumklorid (0, 45%) og glukose opløsning (2, 5%), glukose opløsning 5% eller 10%, dextran 6% i glukose opløsning 5%, hydroxyethylen stivelse, opløsning 6- 10%.
The content of the infusion bottle is dissolved in 40 ml of one of the following calcium-free infusion solutions by swirling, resulting in a concentration of 0.05 g/ ml: sodium chloride solution 0.9%, sodium chloride (0.45%) and glucose (2.5%) solution, glucose solution 5% or 10%, dextran 6% in glucose solution 5%, hydroxyethylen starch solution 6 – 10%.
Se også ” Principiel kemisk intolerance ”.
See also section "Principal chemical intolerances“.
Blandbarhed Som en principsag infusionsopløsninger.
Miscibility As a matter of principle, ceftriaxone solutions must always be administered separately from other solutions for infusion.
Ceftriaxon Tyrol Pharma 2 g bør aldrig blandes med nogen af de følgende opløsninger:
Ceftriaxone Tyrol Pharma 2g must never be mixed with any of the following solutions:
- Ceftriaxon Tyrol Pharma 2 g må ikke administreres i de samme sprøjter som andre
- Ceftriaxone Tyrol Pharma 2g must not be administered in the same syringe as other antibiotics
London, den 21. 08. 06 EMEA/ CHMP/ 212746/ 2006
London, 21 August 2006 EMEA/ CHMP/ 212746/ 2006
21, OM Ceftriaxon Tyrol Pharma og tilknyttede navne Internationalt fællesnavn (INN):
OPINION FOLLOWING AN ARTICLE 29(2)1 REFERRAL FOR Ceftriaxone Tyrol Pharma and associated names International Non-Proprietary Name (INN):
Ceftriaxon Tyrol Pharma og tilknyttede navne 1 og 2 g pulver til injektionsvæske eller infusionsvæske, opløsning, er et antibiotikum, et cephalosporin af tredje generation.
Ceftriaxone Tyrol Pharma and associated names, 1g and 2 g powder for solution for injection/ infusion, is an antibiotic, being a third generation cephalosporin.
Det er indiceret til behandling af følgende infektioner, som skyldes mikroorganismer, der er følsomme over for ceftriaxon og som kræver parenteral behandling: • Sepsis • Bakteriel meningitis • Infektioner i knogler og led • Infektioner i hud og bløddele • Pneumonier Ceftriaxon er indiceret til perioperativ profylakse hos patienter med en vis risiko for alvorlig postoperativ infektion.
It is indicated for the treatment of the following infections when caused by micro-organisms that are susceptible to ceftriaxone and if parenteral treatment is necessary: • sepsis • bacterial meningitis • infections of bones or joints • infections of skin or soft tissues • pneumonia Ceftriaxone is indicated for perioperative prophylaxis in patients with a certain risk of severe postoperative infections.
Sandoz GmbH har indgivet ansøgning om gensidig anerkendelse af Ceftriaxon Tyrol Pharma og tilknyttede navne 1g og 2g opløsning til injektionsvæske eller infusionsvæske, opløsning, på grundlag af en markedsføringstilladelse udstedt af Tyskland den 13. august 2002.
Sandoz GmbH submitted applications for mutual recognition of Ceftriaxone Tyrol Pharma and associated names, 1g and 2g, solution for injection/ infusion on the basis of the marketing authorisation granted by Germany on 13 August 2002.
Dosisanbefalingen til nyfødte omfatter nemlig højere doser til nyfødte mellem 15- 27 dage (80 mg/ kg), mens standarddoseringen i Det Forenede Kongerige er 20- 50mg/ kg til nyfødte mellem 0- 28 dage.
The posology in neonates where higher doses were proposed for neonates aged 15-27 days (80 mg/ kg) while the standard dose is 20-50mg/ kg in the UK for neonates 0-28 days.
Rapportør var dr.
The Rapporteur was Dr.
Broich og medrapportører var dr.
Broich and Co-Rapporteurs were Dr.
Hudson og dr.
Hudson and Dr.
I lyset af de samlede data, der var blevet fremlagt, og den faglige debat i udvalget var CHMP på sit møde i maj 2006 af den opfattelse, at benefit- risk forholdet er gunstigt for Ceftriaxon Tyrol Pharma og
During their May 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Ceftriaxone Tyrol Pharma and associated names, that the objections raised by United Kingdom should
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 86 13 E- mail: mail@ emea. eu. int http: // www. emea. eu. int ©EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged tilknyttede navne, at de af Det Forenede Kongerige rejste indvendinger ikke bør forhindre udstedelse af en markedsføringstilladelse, og at referencemedlemsstatens produktresumé, etikettering og indlægsseddel bør ændres.
(44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: mail@emea. eu. int http: / /www. emea. eu. int ©EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
Den endelige udtalelse blev konverteret til en afgørelse truffet af Europa- Kommissionen den 21. august 2006.
The final opinion was converted into a Decision by the European Commission on 21 August 2006.
London, den 22. august 2007 EMEA/ CHMP/ 248862/ 2007
London, 22 August 2007 EMEA/ CHMP/ 248862/ 2007
41, OM
OPINION FOLLOWING AN ARTICLE 29(4)1 REFERRAL FOR
Cefuroximaxetil og tilknyttede navne Internationalt fællesnavn (INN): cefuroxim (som axetil)
Cefuroximaxetil and associated names International Non-Proprietary Name (INN): cefuroxime (as axetil)
BAGGRUNDSOPLYSNINGER Cefuroximaxetil og tilknyttede navne, 125 mg, 250 mg og 500 mg overtrukne tabletter, er et cephalosporin (gruppen af β- lactam- antibiotika), indiceret til behandling af lette til moderate/ svære infektioner, som skyldes mikroorganismer, der er følsomme over for cefuroxim, f. eks.:
BACKGROUND INFORMATION Cefuroximaxetil and associated names, 125 mg, 250 mg and 500 mg, coated tablets is a cephalosporin (β - lactam group of antibiotics), indicated for the treatment of mild to moderately severe infections caused by micro-organisms susceptible to cefuroxime, such as:
- øvre luftvejsinfektioner: akut otitis media, sinusitis, tonsillitis og pharyngitis
- upper respiratory tract infections: acute otitis media, sinusitis, tonsillitis and pharyngitis
- akut bronkitis, akutte eksacerbationer af kronisk bronkitis
- acute bronchitis, acute exacerbations of chronic bronchitis
- ukomplicerede urinvejsinfektioner: cystitis
- lower uncomplicated urinary tract infections: cystitis
- hud - og bløddelsinfektioner: furunkulose, pyoderma og impetigo
- skin and soft tissue infections: furunculosis, pyoderma and impetigo
- ukompliceret gonorré: uretritis og cervicitis
- uncomplicated gonorrhoea: urethritis and cervicitis
- behandling af tidlige stadier af Lyme- sygdom (stadium I) og efterfølgende forebyggelse af sene
- treatment of early stage Lyme disease (stadium I) and subsequent prevention of late complications in
komplikationer hos voksne og børn over 12 år.
adults and children above 12 years of age.
Sandoz B. V. indgav ansøgninger om gensidig anerkendelse af Cefuroximaxetil og tilknyttede navne, 125 mg, 250 mg og 500 mg overtrukne tabletter, på grundlag af den markedsføringstilladelse, som Nederlandene udstedte den 1. oktober 2004.
Sandoz B. V. submitted applications for mutual recognition of Cefuroximaxetil and associated names, 125 mg, 250 mg and 500 mg, coated tablets on the basis of the marketing authorisation granted by the Netherlands on 1 October 2004.
Der blev identificeret betydelige forskelle med hensyn til indikationen “ ukompliceret gonorré: uretritis og cervicitis ”.
Significant difference was identified with regard to the indication “ uncomplicated gonorrhoea: urethritis and cervicitis”.
Dette vedrører sikkerheden og virkningen af cefuroximaxetil ved ukompliceret gonorré og risk/ benefit- forholdet for den ansøgte indikation, hvilket blev anset for at udgøre et alvorligt problem for folkesundheden.
This refers to the safety and efficacy of cefuroximaxetil in uncomplicated gonorrhoea and risk- benefit balance for this sought indication and this was considered to be a serious public health concern.
Rapportøren var dr.
The arbitration procedure started on 18 October 2006 with the adoption of a list of questions.
De eksisterende markedsføringstilladelser skulle ændres, og ikke- færdigbehandlede ansøgninger om markedsføringstilladelse skulle godkendes med disse ændringer.
Existing Marketing Authorisations should be varied and pending Marketing Authorisation Applications should be granted to include these amendments.
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 86 13 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Listen over de pågældende lægemiddelnavne fremgår af bilag I.
(44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged The list of the product names concerned is given in Annex I.
Den endelige udtalelse blev konverteret til en afgørelse truffet af Europa- Kommissionen den 22. august 2007.
The final opinion was converted into a Decision by the European Commission on 22 August 2007.
FORTEGNELSE OVER LÆGEMIDLERNES NAVNE, LÆGEMIDDELFORM( ER), STYRKE( R), INDGIVELSESVEJ( E), ANSØGER( E), INDEHAVER( E) AF MARKEDSFØRINGSTILLADELSE( R) I MEDLEMSSTATERNE
LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDER / APPLICANTS IN THE MEMBER STATES
Særnavn
Marketing
Lægemiddel -
Invented name
Medlemsstat
Route of
markeds - føringstilladelse
Member State Authorisation Holder
form
Form
Holland
administration
Veluwezoom 22 1327 Almere Holland
Veluwezoom 22 1327 Almere The Netherlands
Cefuroximaxetil 125, omhulde tabletten 125 mg Cefuroximaxetil 250, omhulde tabletten 250 mg Cefuroximaxetil 500, omhulde tabletten 500 mg
Cefuroximaxetil 125, omhulde tabletten Cefuroximaxetil 250, omhulde tabletten Cefuroximaxetil 500, omhulde tabletten
Overtrukne tabletter
125 mg 250 mg 500 mg
oral brug
oral use
1A Pharma GmbH Keltenring 1 + 3 D- 82041 Oberhaching Tyskland
1A Pharma GmbH Keltenring 1 + 3 D-82041 Oberhaching Germany
Cefuroxim 1A Pharma Cefuroxim 1A Pharma Cefuroxim 1A Pharma
Cefuroxim 1A Pharma 125 mg Cefuroxim 1A Pharma 250 mg Cefuroxim 1A Pharma 500 mg
Overtrukne tabletter
Coated tablets
Cefuroxime axetil Cefuroxime axetil
Cefuroxime axetil Sandoz 250 mg Cefuroxime axetil Sandoz 500 mg
CEFUROXIMA Sandoz COMPRIMIDOS CEFUROXIMA Sandoz COMPRIMIDOS
CEFUROXIMA Sandoz CEFUROXIMA Sandoz
250 mg 500 mg
250 mg COMPRIMIDOS 250 mg 500 mg COMPRIMIDOS 500 mg
comprimidos
125 mg comprimidos 125 mg
Overtrukne
Coated tablets
Gran Vía de les Corts Catalanes, 764 08013 Barcelona Spanien
Gran Vía de les Corts Catalanes, 764 08013 Barcelona Spain